Ptcbio
NASDAQ: PTCTSouth Plainfield, US · Founded 1998 · 1,148 employees on LinkedIn · 2 known investors
Find your way into Ptcbio
181 people in our graph share verified history with the Ptcbio team — schools, employers, funds. One of them is your warm intro.
Bob Stefanskiunlockedknows Mark E. Boulding · together at University of Michigan Law School (overlapped)
×2knows the team · via White & Case
×4knows the team · via Yale University
×5knows the team · via University of Michigan Law School
PTC is a global pharmaceutical company focused on the discovery, development, and commercialization of medicines for patients with rare diseases who have few or no treatment options. It combines clinical and scientific expertise to bring these treatments to patients worldwide.
Founders & leadership
Ptcbio was founded in 1998 by Stuart W. Peltz, Allan S. Jacobson, and Allan Jacobson.
SW
Stuart W. PeltzCo-founder
AS
Allan S. JacobsoninCo-founder
AJ
Allan JacobsoninCo-founder
ME
Mark E. BouldinginExecutive Vice President and Chief Legal OfficerMark Boulding is Executive Vice President and Chief Legal Officer of PTC Therapeutics, a pharmaceutical company developing medicines for rare diseases. He previously held senior legal and executive roles at MedicaLogic/Medscape and Medscape, and practiced as a partner at Washington, D.C. law firms; he holds a J.D. from the University of Michigan and a B.A. from Yale College.
CU
Christine UtterinChief Accounting Officer (CAO) and Head of People ServiesExecutive Officer at Ptc Therapeutics
MS
NA
MB
Matthew B. KleininChief Executive Officer and President
MS
Michael SchmertzlerNamed on SEC filing
Board
DS
Dawn SvoronosBoard director
DP
David P. SouthwellBoard director
GD
Glenn D. Steele, Jr.Board director
Investors · 2
Reported raises · per SEC filings
Form D private placements$368.8M disclosed across 4 rounds · 2018–2023
▶$35.9MraisedMay 2023 · 40 investors · BiotechnologyRule 506(b)
▶$35.9MraisedMay 2023 · 40 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Stepanie S. OkeyDirector
- Michael SchmertzlerDirector
- Matthew B. Klein, M.D.Executive Officer, Director
- Eric PauwelsExecutive Officer
- Alethia YoungDirector
- Neil Almstead, Ph.DExecutive Officer
- Glenn D. Steele Jr., M.D., Ph.D.Director
- David P. SouthwellDirector
- Emily HillExecutive Officer
- Jerome B. Zeldis, M.D., Ph.D.Director
- Mark E. BouldingExecutive Officer
- Christine UtterExecutive Officer
- Allan Jacobson, Ph.D.Director
- Emma ReeveDirector
- Mary SmithDirector
- Offering amount
- $35.9M
- Amount sold
- $35.9M
- First sale
- Apr 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$41.9MraisedJun 2020 · 38 investors · BiotechnologyRule 506(b)
▶$41.9MraisedJun 2020 · 38 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mark E. BouldingExecutive Officer
- Stuart W. PeltzExecutive Officer, Director
- Matthew KleinExecutive Officer
- David P. SouthwellDirector
- Michael SchmertzlerDirector
- Christine UtterExecutive Officer
- Emily HillExecutive Officer
- Eric PauwelsExecutive Officer
- Stephanie S. OkeyDirector
- Glenn D. Steele, Jr.Director
- Dawn SvoronosDirector
- Jerome B. ZeldisDirector
- Allan S. JacobsonDirector
- Emma ReeveDirector
- Neil AlmsteadExecutive Officer
- Offering amount
- $41.9M
- Amount sold
- $41.9M
- First sale
- May 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$140.9MraisedMay 2020 · 57 investors · BiotechnologyRule 506(b)
▶$140.9MraisedMay 2020 · 57 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Emma ReeveDirector
- Jerome B. ZeldisDirector
- Christine UtterExecutive Officer
- Dawn SvoronosDirector
- Glenn D. Steele, Jr.Director
- Stephanie S. OkeyDirector
- Mark E. BouldingExecutive Officer
- Emily HillExecutive Officer
- Eric PauwelsExecutive Officer
- David P. SouthwellDirector
- Michael SchmertzlerDirector
- Stuart W. PeltzExecutive Officer, Director
- Allan S. JacobsonDirector
- Matthew B. KleinExecutive Officer
- Neil AlmsteadExecutive Officer
- Offering amount
- $140.9M
- Amount sold
- $140.9M
- Sales commissions
- $1.7M
- Placement agents
- SVB Leerink LLC
- First sale
- Apr 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$150MraisedSep 2018 · 52 investors · BiotechnologyRule 506(b)
▶$150MraisedSep 2018 · 52 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Dawn SvoronosDirector
- Stuart W. PeltzExecutive Officer, Director
- David P. SouthwellDirector
- Allan S. JacobsonDirector
- Mark E. BouldingExecutive Officer
- Christine UtterExecutive Officer
- Michael SchmertzlerDirector
- Glenn D. Steele, Jr.Director
- Marcio SouzaExecutive Officer
- Jerome B. ZeldisDirector
- Neil AlmsteadExecutive Officer
- Offering amount
- $150M
- Amount sold
- $150M
- First sale
- Aug 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Ptcbio do?
- PTC is a global pharmaceutical company focused on the discovery, development, and commercialization of medicines for patients with rare diseases who have few or no treatment options. It combines clinical and scientific expertise to bring these treatments to patients worldwide.
- Who founded Ptcbio?
- Ptcbio was founded by Stuart W. Peltz, Allan S. Jacobson, Allan Jacobson in 1998.
- Who are Ptcbio's investors?
- Ptcbio's investors include Bay City Capital, Longwood Fund.
- How much funding has Ptcbio raised?
- Ptcbio has disclosed $368.8M raised across 4 rounds.
- Where is Ptcbio headquartered?
- Ptcbio is headquartered in South Plainfield, US.